U.S. Major Depressive Disorder (MDD) Market Analysis & Outlook 2018-2022 - Players Featured are Pfizer, AstraZeneca, Eli Lilly & Company, and Lundbeck - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 21, 2018--The “U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2022)” report has been added to ResearchAndMarkets.com’s offering.
The report provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. market.
The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
MDD is the most common mental disorder in the U.S. Approximately 16 million American adults suffer from the major depressive disorder and about one-third of the MDD patient remain untreated. The number of treated patients is projected to rise on account of better medical access and rising awareness regarding depression.
There are few potential drugs in development that are being developed with improved efficacy and safety for the treatment of MDD and are expected to contribute significantly to the market growth in the U.S.
Growth DriversGrowing Aging Population Rising Female Population Increasing Spending on Prescription Drugs Increasing Prevalence of Depression Growing Mental Health Expenditure Unmet Need
Key Trends & DevelopmentsIncreasing Awareness for Depression Direct to Customer Advertising Rapid Acting Drugs In Development Rising Number of Mental Health Programs
ChallengesStringent Drug Regulations Patent Expiry of Drugs Complications and Side Effects associated with Anti-depressants Availability of Other Therapies such as Meditation and Psychotherapy
Key Topics Covered
1. Market Overview
2. The U.S. MDD Market
3. Market Dynamics
4. Competitive Landscape
5. Company ProfilesPfizer Inc. AstraZeneca Eli Lilly & Company Lundbeck
For more information about this report visit https://www.researchandmarkets.com/research/3hp8cs/u_s_major?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180821005590/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Mental Disorders Drugs
KEYWORD: UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/21/2018 01:43 PM/DISC: 08/21/2018 01:43 PM